FUNDAMENTALS
EdgeFII/DII
ALKEMAlkem Laboratories
₹5,185.00+0.78%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
ALKEMNSE · EquityPharmaceuticals

Alkem Laboratories

ISIN
INE540L01014
Instrument key
NSE_EQ|INE540L01014
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹5,185.00+40.00 · +0.78%
Day rangecircuit ₹4,666.50 – ₹5,703.50
5,114.00
5,185.00

as of 21/11/2026, 1:47:57 pm

Open
₹5,154.50
Day high
₹5,185.00
Day low
₹5,114.00
Prev. close
₹5,145.00
Volume
69.6K
VWAP
₹5,155.25

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 day · 5-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX

No candles for this range

Intraday candles are empty outside market hours — pick a longer range.

Candle data0 rows of open, high, low, close and volumeShowHide

No candles in this range

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

29.54
Company
29.54
Sector
-45.02

Worse than sector by 166%

P/B

Price ÷ book value per share

4.16
Company
4.16
Sector
4.21

Better than sector by 1%

ROA

Net income ÷ total assets

9.08%
Company
9.08%
Sector
1.19%

Better than sector by 663%

ROE

Net income ÷ shareholders' equity

13.91%
Company
13.91%
Sector
-0.4%

Better than sector by 3578%

ROCE

EBIT ÷ capital employed

17.87%
Company
17.87%
Sector
15.44%

Better than sector by 16%

Quick Ratio

Liquid assets ÷ current liabilities

1.86
Company
1.86
Sector
4.8

Worse than sector by 61%

EV/EBITDA

Enterprise value ÷ EBITDA

17.49
Company
17.49
Sector
22.86

Better than sector by 23%

04/Business

About the company

Sector: Pharmaceuticals

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.

Sector market cap (INR)
₹61,799 Cr

reported in crore

Sector market cap (USD)
$6.87B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Standalone income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹10,219 Cr
+9.64% vs Mar 2025
Net profit · Mar 2026
₹2,282 Cr
+0.05% vs Mar 2025
Operating margin
24.7%
was 24.7%
Revenue CAGR · 4p
3.1%
profit 26.2% · op 23.9%
Filed order
Revenue10,2199,3218,2709,321
Revenue growthreported9.6%12.7%-11.3%—
Operating profit2,5232,3041,5941,327
Operating profit growthreported9.5%44.5%20.1%—
Operating marginderived24.7%24.7%19.3%14.2%
Net profit2,2822,2811,7471,134
Net profit growthreported0.1%30.6%54.0%—
Net marginderived22.3%24.5%21.1%12.2%
EPS — basic₹/share, annual190.87190.77146.1394.88

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue9,6648,8137,9649,055
Other Income555507306266
Total Revenue10,2199,3218,2709,321
Total Expenses7,5537,0176,6127,994
Profit Before Tax2,5232,3041,5941,327
Tax33821434193
Profit After Tax2,1852,0901,5611,134
EPS - Basic190.87190.77146.1394.88
EPS - Diluted190.87190.77146.1394.88

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Standalone balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹17,261 Cr
+10.68% YoY
Total liabilities
₹3,262 Cr
Net worth
₹13,999 Cr
Liabilities ÷ assets
18.9%
lower means a lighter balance sheet
Filed order
Total assets17,26115,59614,03812,731
Total liabilities3,2623,2743,4833,381
Net worthderived13,99912,32210,5559,350
Liabilities ÷ assetsderived18.9%21.0%24.8%26.6%
Asset growthderived10.7%11.1%10.3%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets9,4318,2425,9985,959
Current Assets7,8307,3548,0406,772
Total Assets17,26115,59614,03812,731
Current Liabilities2,7472,5433,1063,045
Net Current Asset5,0834,8114,9343,727
Non-Current Liabilities516730377337
Equity Capital13,99912,32210,5559,350
Total Equity & Liabilities17,26115,59614,03812,731

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Standalone cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹1,969 Cr
-10.06% YoY
Investing
-₹1,461 Cr
Financing
-₹673 Cr
Free cash flow
₹508 Cr
operating + investing
Filed order
Operating activities1,9692,1891,6871,437
Operating changereported-10.1%29.8%17.3%—
Investing activities-1,461-1,007-866197
Investing changereported-45.0%-16.4%-539.3%—
Financing activities-673-1,037-959-1,711
Financing changereported35.1%-8.1%44.0%—
Net cash flowderived-165145-138-77
Free cash flowoperating + investing5081,1828211,634

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax2,6722,5971,8811,327
Income before WC changes2,6072,5462,0931,456
Change in Assets-250-179-238169
Change in Liabilities9421918537
Change in WC-15640-53206
Cash flow from Operations1,9692,1891,6871,437
Cash flow from Investing-1,461-1,007-866197
Cash flow from Financing-673-1,037-959-1,711
Total Cash Flow-165145-138-77
Cash (Start of the year)12-133582
Cash (End of the year)-15312-1335

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
49.70%
0.00 pts QoQ
FII
10.32%
-0.10 pts QoQ
DII (other)
5.04%
-0.89 pts QoQ
Mutual funds
17.79%
+1.08 pts QoQ
Retail & others
17.15%
-0.10 pts QoQ
Filed order
Promoters49.7%49.7%51.2%51.2%
FII10.3%10.4%10.2%10.0%
DII (other)5.0%5.9%5.8%5.5%
Mutual funds17.8%16.7%15.6%16.1%
Retail & others17.1%17.3%17.3%17.3%
Promoters — QoQ changepts, derived0.0%-1.5%0.0%—
FII — QoQ changepts, derived-0.1%0.3%0.2%—
DII (other) — QoQ changepts, derived-0.9%0.1%0.3%—
Mutual funds — QoQ changepts, derived1.1%1.1%-0.5%—
Retail & others — QoQ changepts, derived-0.1%0.0%-0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹10.00500.0%07 Aug 202607 Aug 202629 May 2026
DividendInterim₹43.002150.0%20 Feb 202620 Feb 202613 Feb 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility
    2d ago19/11/2026, 2:07:35 pm
    Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility

    Alkem Labs stated that it continues to manufacture and supply approved products from the said facility to the US market, adding that there is no material impact on current operations, financial, or other activities of the company.

  • Thumbnail: Groww shares worth ₹1,905 crore changes hands in block deal; Alkem Labs sees trade worth ₹300 crore
    4d ago17/11/2026, 9:31:34 pm
    Groww shares worth ₹1,905 crore changes hands in block deal; Alkem Labs sees trade worth ₹300 crore

    On Tuesday, venture capital firm Ribbit Capital’s investment entities, Ribbit Capital V and Ribbit Cayman GW Holdings V Ltd, sold a total of 8.7 crore shares of Groww for ₹1,905.3 crore.

Showing 1–2 of 2 articles